AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04218409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oral oxycodone 5 mg orally
Study NCT04218409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal oxytocin administration (48 IU)
Study NCT04218409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oxycodone
Description: Oxycodone 0 mg orally
Study NCT04218409 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Oxycodone
Description: Oxycodone 0 mg orally
Study NCT04218409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oxytocin
Description: Intranasal placebo administration
Study NCT04218409 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo oxytocin
Description: Intranasal placebo administration
Study NCT04218409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oral oxycodone 2.5 mg orally
Study NCT04234867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: once daily for 5 days
Study NCT04234867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: once daily for 5 days
Study NCT06334627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Primary Intervention
Description: School readiness intervention
Study NCT04234867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress
Description: single dose after last administration of experimental drug
Study NCT04234867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stress
Description: single dose after last administration of experimental drug
Study NCT04234867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Stress
Description: single dose after last administration of experimental drug
Study NCT04234867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Stress
Description: single dose after last administration of experimental drug
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 6.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 12.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 18.75mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 25.0mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 31.25mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTx-1301 - Dexmethylphenidate 37.5mg
Description: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
Study NCT05924594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
Study NCT06017180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
Study NCT06017180 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial release technique
Description: It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
Study NCT04837573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sister Circle protocol
Description: The intervention is an 8-week, therapeutically-informed protocol.
Study NCT04837573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sister Circle protocol
Description: The intervention is an 8-week, therapeutically-informed protocol.
Study NCT05729932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled vaporized cannabis
Description: Double-blind cannabis and placebo doses, administered through vaporizer
Study NCT05729932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intransal opioid
Description: Double-blind opioid and placebo doses, administered intranasal route
Study NCT02050009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT06486571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography recording with HD-sEMG
Description: Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
Study NCT06486571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
Study NCT04844554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS 3mA
Description: This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
Study NCT04844554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham HD-tDCS
Description: This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
Study NCT04631432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-screening
Description: Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
Study NCT04631432 — intervention group
Intervention type: BEHAVIORAL
Intervention: Task session
Description: The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)
Study NCT04595617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibodies screening
Description: All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
Study NCT05624515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Active trigger point puncture of the angularis scapulae muscle
Study NCT05624515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic compression
Description: Ischaemic compression at the active trigger point of the angularis scapulae muscle
Study NCT06132711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRIL-BAFF-Bicephali CAR-T cells
Description: Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
Study NCT05252169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip.
Study NCT05252169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes.
Study NCT05252169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Physical therapy
Description: Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes.
Study NCT05936788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique
Description: Group A will receive ACBTs with 1 session a day for total 2 days in a week.
Study NCT05936788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing
Description: Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
Study NCT04985825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imgatuzumab
Description: Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
Study NCT06289010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Childhood-Depression (FFT-CD)
Description: This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors.
Study NCT05665816 — intervention group
Intervention type: DEVICE
Intervention: Stent PULSAR® -18 T3,
Description: Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions.
Study NCT05199714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study NCT05199714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study NCT05199714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
Study NCT05199714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.
Study NCT05199714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Description: Aspart insulin delivered in a basal-bolus manner.
Study NCT05744635 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Tacrolimus received as part of routine clinical care
Study NCT05289037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 (B.1.1.529)
Description: A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 (B.1.351)
Description: A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 bivalent (wildtype and Omicron BA.1)
Description: A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)
Description: A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM [B.1.351]
Description: Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM/D614
Description: Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM/D614+B.1.351
Description: Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
Study NCT05289037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Study NCT06226727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019
Description: One tablet administered alone
Study NCT06226727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: One tablet administered alone
Study NCT06226727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: One tablet administered alone
Study NCT02050009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02050009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02050009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05586984 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic uterine lateral suspension
Description: Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
Study NCT05586984 — intervention group
Intervention type: PROCEDURE
Intervention: Transvaginal sacrospinous fixation
Description: Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
Study NCT05163249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study NCT05163249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study NCT05163249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study NCT05732103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-712
Description: CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
Study NCT06017362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Topical insulin 1UI/ml 4 times a day
Study NCT06017362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: Artificial tears 4 times a day
Study NCT04937543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled beclametasone
Description: Adding belcamethasone to standard of care for Covid 19 positive patients
Study NCT04937543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inahaled beclomethasone / formoterol / glycopyrronium
Description: Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
Study NCT00781482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone, zolpidem, placebo
Description: In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.